



Achillion Pharmaceuticals
Investor Relations Department
300 George St.
New Haven, CT 06511
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ACHN

Last Trade: 3.20

Trade Time: 4:00 PM ET
Feb 16, 2018

Change: 0.13 ↑ (+4.235%)

Day Range 3.07 - 3.24

52-Week Range 2.58 - 5.66

Volume 8,034,929

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 9, 2018

[Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference](#)

Dec 20, 2017

[Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D](#)

Dec 18, 2017

[Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy \(C3G\) and the Initiation of a Phase 1 Extended-Release Bioavailability Study](#)

Nov 15, 2017

[Achillion Announces Pricing of Secondary Offering Of Common Stock](#)

Nov 14, 2017

[Achillion Announces Proposed Secondary Offering of Common Stock](#)

Financial Disclosures [\[View all \]](#)

[Third Quarter Financial Results](#)

Feb 23, 2017

[Annual Report \(10-K\)](#)

Apr 17, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)